D R Lowy

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Papillomaviruses: prophylactic vaccine prospects
    D R Lowy
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Biochim Biophys Acta 1423:M1-8. 1999
  2. pmc Prophylactic human papillomavirus vaccines
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 116:1167-73. 2006
  3. ncbi request reprint Papillomavirus-like particle based vaccines: cervical cancer and beyond
    J T Schiller
    National Cancer Institute, Bethesda, MD, USA
    Expert Opin Biol Ther 1:571-81. 2001
  4. pmc Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
    R Kirnbauer
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 89:12180-4. 1992
  5. pmc L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation
    M M Okun
    Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 75:4332-42. 2001
  6. ncbi request reprint Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
    R B Roden
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4040, USA
    Virology 270:254-7. 2000
  7. pmc Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope
    R B Roden
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 71:6247-52. 1997
  8. pmc The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation
    M S Barbosa
    Laboratory of Cellular Oncology, National Cancer Institute, NIH Bethesda, MD 20892
    EMBO J 9:153-60. 1990
  9. ncbi request reprint Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene
    T J Velu
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892
    Science 238:1408-10. 1987
  10. ncbi request reprint The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors
    P Martin
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    Cell 59:21-32. 1989

Collaborators

Detail Information

Publications61

  1. ncbi request reprint Papillomaviruses: prophylactic vaccine prospects
    D R Lowy
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
    Biochim Biophys Acta 1423:M1-8. 1999
    ..Since prospective efficacy trials will take several years to complete, considering alternative approaches is also worthwhile...
  2. pmc Prophylactic human papillomavirus vaccines
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 116:1167-73. 2006
    ..Unresolved issues include the most critical groups to vaccinate and when the vaccine's cost may be low enough for widespread implementation in the developing world, where 80% of cervical cancer occurs...
  3. ncbi request reprint Papillomavirus-like particle based vaccines: cervical cancer and beyond
    J T Schiller
    National Cancer Institute, Bethesda, MD, USA
    Expert Opin Biol Ther 1:571-81. 2001
    ..Vaccines based on this approach could potentially be effective alternatives to monoclonal antibody (mAb)-based therapies for a variety of disease targets...
  4. pmc Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
    R Kirnbauer
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 89:12180-4. 1992
    ..This type of L1 preparation might be considered as a candidate for a serological test to measure antibodies to conformational virion epitopes and for a vaccine to prevent papillomavirus infection...
  5. pmc L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation
    M M Okun
    Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 75:4332-42. 2001
    ..We conclude that the L1-binding domain located near the C terminus of L2 may bind L1 prior to completion of capsid assembly, and that both L1-binding domains of L2 are required for efficient encapsidation of the viral genome...
  6. ncbi request reprint Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
    R B Roden
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4040, USA
    Virology 270:254-7. 2000
    ..This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection...
  7. pmc Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope
    R B Roden
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 71:6247-52. 1997
    ..E70 to L1 virus-like particles of the two variants. A substitution at residue 282 of L1 was responsible for this differential reactivity, suggesting that this residue constitutes part of the H16.E70 epitope...
  8. pmc The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation
    M S Barbosa
    Laboratory of Cellular Oncology, National Cancer Institute, NIH Bethesda, MD 20892
    EMBO J 9:153-60. 1990
    ....
  9. ncbi request reprint Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene
    T J Velu
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892
    Science 238:1408-10. 1987
    ....
  10. ncbi request reprint The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors
    P Martin
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    Cell 59:21-32. 1989
    ..We conclude that E5 may enhance the receptor activity via inhibition of receptor down-modulation...
  11. ncbi request reprint Papillomavirus-like particles induce acute activation of dendritic cells
    P Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 166:5346-55. 2001
    ..These results offer a mechanistic explanation for the striking ability of papillomavirus VLP-based vaccines to induce potent T and B cell responses even in the absence of adjuvant...
  12. ncbi request reprint NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16
    D V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, 20892, USA
    Virology 279:361-9. 2001
    ..Vaccination with HPV16 114K L1 VLPs generates antibodies that should confer a similar degree of protection against all known phylogenetic branches of HPV16...
  13. pmc Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins
    R M Melillo
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    Mol Cell Biol 14:8241-9. 1994
    ....
  14. pmc E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases
    L Asnaghi
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Oncogene 29:2760-71. 2010
    ..These proteins can be considered downstream effectors of E-cadherin and might represent therapeutic targets in some NSCLC...
  15. pmc Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation in vitro and oncogenicity in vivo
    T J Velu
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    J Virol 63:1384-92. 1989
    ....
  16. ncbi request reprint Identification of small clusters of divergent amino acids that mediate the opposing effects of ras and Krev-1
    K Zhang
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892
    Science 249:162-5. 1990
    ..Because this region in Ras proteins has been implicated in effector function, the results suggest that Krev-1 suppresses ras-induced transformation by interfering with interaction of Ras with its effector...
  17. pmc In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential
    M S Barbosa
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    J Virol 65:292-8. 1991
    ..These same factors may, in part, account for the apparent difference in oncogenic potential between these viruses...
  18. ncbi request reprint Selective potentiation of c-fps/fes transforming activity by a phosphatase inhibitor
    R A Feldman
    Laboratory of Cellular Oncology National Cancer Institute, Bethesda, Maryland 20892
    Oncogene Res 5:187-97. 1990
    ..The specificity of the biological response of c-fps/fes to the stabilization of phosphotyrosine suggests that this molecule has a distinct mode of regulation and mechanism of action...
  19. pmc Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies
    B Chackerian
    Laboratory of Cellular Oncology, National Institutes of Health, Bethesda, Maryland 20892-4040, USA
    J Clin Invest 108:415-23. 2001
    ..Together, these results suggest a potentially flexible method to efficiently generate autoantibodies against specific self-proteins that mediate arthritis and other diseases...
  20. pmc N terminus of Sos1 Ras exchange factor: critical roles for the Dbl and pleckstrin homology domains
    X Qian
    Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    Mol Cell Biol 18:771-8. 1998
    ..We conclude that the Dbl and PH domains are critical for Sos function and that stable association of Sos with activated EGF receptors requires both the Sos N and C termini...
  21. pmc Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf
    P H Anborgh
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892, USA
    Mol Cell Biol 19:4611-22. 1999
    ....
  22. doi request reprint Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick Inc, NCI Frederick, Building 469, Room 120, Frederick, MD 21702, USA
    Vaccine 26:3608-16. 2008
    ....
  23. pmc Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection
    Rebecca M Richards
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:1522-7. 2006
    ..However, to our knowledge, furin has not been previously implicated in the viral entry process. This step is potentially a target for PV inhibition...
  24. pmc Human alpha-defensins block papillomavirus infection
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892 4263, USA
    Proc Natl Acad Sci U S A 103:1516-21. 2006
    ....
  25. pmc Carrageenan is a potent inhibitor of papillomavirus infection
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA
    PLoS Pathog 2:e69. 2006
    ..Some of these products block HPV infectivity in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products are effective as topical microbicides against genital HPVs...
  26. ncbi request reprint Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    HPV Immunology Laboratory, SAIC Frederick, Inc NCI Frederick, Frederick Building 469, Room 120, Frederick, MD 21702, USA
    Virology 353:451-62. 2006
    ..In summary, PBMC from HPV-16 VLP vaccine recipients can respond to L1VLP from heterologous HPV types, suggesting the presence of conserved T cell epitopes...
  27. ncbi request reprint Chapter 12: Prophylactic HPV vaccines: underlying mechanisms
    Margaret Stanley
    Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, UK
    Vaccine 24:S3/106-13. 2006
    ..Important issues remaining to be addressed include the duration of protection and genotype replacement...
  28. ncbi request reprint Prospects for cervical cancer prevention by human papillomavirus vaccination
    John T Schiller
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:10229-32. 2006
    ..These include duration of protection, degree of cross-protection against nonvaccine types, efficacy in men, and vaccine availability to economically disadvantaged women...
  29. pmc Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition
    Patricia M Day
    Laboratory of Cellular Oncology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 81:8784-92. 2007
    ..We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes...
  30. pmc Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles
    Alfonso Garcia-Pineres
    HPV Immunology Laboratory, SAIC Frederick, Inc NCI Frederick, Frederick, Maryland 21702, USA
    Clin Vaccine Immunol 14:984-9. 2007
    ..Cytokine profiling studies using samples from efficacy trials may provide important information about discriminators of long-term protection against HPV...
  31. ncbi request reprint Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
    Allan Hildesheim
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    JAMA 298:743-53. 2007
    ..Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and development of cervical precancers and cancer. Women with oncogenic HPV infections might consider vaccination as therapy...
  32. pmc Arrangement of L2 within the papillomavirus capsid
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
    J Virol 82:5190-7. 2008
    ..This structural information should facilitate investigation of L2 function during the assembly and entry phases of the papillomavirus life cycle...
  33. pmc Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Clin Vaccine Immunol 15:60-4. 2008
    ..2% and 93.5%, respectively, suggesting that Merocel sponges are more appropriate for specimen collection. The SEAPNA can be applied to determine the surrogates of protection and to examine the durability of protection at the cervix...
  34. pmc Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies
    Patricia M Day
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 82:4638-46. 2008
    ..These findings suggest a dynamic model of virion-cell surface interactions that has implications for both evolution of viral serotypes and the efficacy of current and future HPV vaccines...
  35. ncbi request reprint Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 337:365-72. 2005
    ..BPV1 L2 was exceptionally effective at inducing cross-neutralizing antibodies to these shared epitopes...
  36. ncbi request reprint Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine
    Denise Nardelli-Haefliger
    Department of Gynecology, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Vaccine 23:3634-41. 2005
    ..Our data suggest that aerosol administration of HPV VLPs may represent a potential alternative to parenteral injection...
  37. ncbi request reprint HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood
    Ligia A Pinto
    SAIC Frederick, Inc NCI Frederick, Room 120, Building 469, Frederick, MD 21702, USA
    Vaccine 23:3555-64. 2005
    ....
  38. ncbi request reprint Papillomaviruses infect cells via a clathrin-dependent pathway
    Patricia M Day
    Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Building 36, Room 1D 32, Bethesda, MD 20892, USA
    Virology 307:1-11. 2003
    ..Surprisingly, the kinetics of internalization were unusually slow for this mechanism, with the t(1/2) of entry of BPV-1 being approximately 4 h versus 5-15 min for a typical ligand...
  39. ncbi request reprint p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB
    Shuling Zhang
    Laboratory of Genetics, Center for Cancer Research, Bethesda, MD 20892 4255, USA
    Oncogene 22:2285-95. 2003
    ..BALB/c mice have both regulatory and coding region defects that may contribute to the impairment of p16 gene function...
  40. ncbi request reprint Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells
    Petra Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4040, USA
    Clin Immunol 106:231-7. 2003
    ..Our results indicate that VLPs target multiple cells of the immune system, which helps to account for VLPs being so effective in priming humoral and cellular immune responses even in the absence of adjuvant...
  41. ncbi request reprint Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    SAIC Frederick, Inc National Cancer Institute, Building 469, Room 120, Frederick, MD 21702, USA
    J Infect Dis 188:327-38. 2003
    ..Future efficacy studies are needed to evaluate whether and/or how VLP vaccines confer protection against genital HPV infection and associated disease...
  42. ncbi request reprint Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles
    Denise Nardelli-Haefliger
    Department of Gynecology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Natl Cancer Inst 95:1128-37. 2003
    ..Therefore, we determined the levels of total and specific antibodies in the cervical secretions of women who had been immunized with HPV16 VLPs and examined the influence of the menstrual cycle and oral contraceptive use on these levels...
  43. ncbi request reprint A new link between Fanconi anemia and human papillomavirus-associated malignancies
    Douglas R Lowy
    J Natl Cancer Inst 95:1648-50. 2003
  44. pmc Efficient intracellular assembly of papillomaviral vectors
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4263, USA
    J Virol 78:751-7. 2004
    ..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism...
  45. pmc Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus
    Bryce Chackerian
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:4037-47. 2004
    ....
  46. ncbi request reprint Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells
    Petra Lenz
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, USA
    Eur J Immunol 35:1548-56. 2005
    ..Finally, CpG-activated pDC, but not pDC exposed to HPV16 VLP, activated lymphocytes to secrete IL-10 and low levels of IFN-gamma. Together these findings suggest a possible immunogenic effect of pDC in the setting of VLP vaccination...
  47. pmc Maturation of papillomavirus capsids
    Christopher B Buck
    Laboratory of Cellular Oncology, Building 37, Room 4106, 9000 Rockville Pike, Bethesda, MD 20892 4263, USA
    J Virol 79:2839-46. 2005
    ..Despite their obvious morphological differences, mature and immature capsids are similarly neutralizable by various L1- and L2-specific antibodies...
  48. ncbi request reprint Determinants of autoantibody induction by conjugated papillomavirus virus-like particles
    Bryce Chackerian
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:6120-6. 2002
    ....
  49. pmc Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression
    Patricia M Day
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:14252-7. 2004
    ..The results identify a role for PML in the enhancement of viral infectivity in the early part of the life cycle. We propose a model in which L2 chaperones the viral genome to ND10 to efficiently initiate viral transcription...
  50. doi request reprint Human papillomavirus infection and the primary and secondary prevention of cervical cancer
    Douglas R Lowy
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 113:1980-93. 2008
    ..The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer...
  51. ncbi request reprint Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 321:205-16. 2004
    ..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies...
  52. pmc Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities
    Xiaolan Qian
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:9012-7. 2007
    ..The results suggest that DLC1 is a multifunctional protein whose biological activity depends on cooperation between its tensin binding and RhoGAP activities, although neither activity depends on the other...
  53. pmc Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
    Rolando Herrero
    Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, Torre La Sabana, 300 Oeste del ICE, Piso 7, Sabana Norte, San Jose, Costa Rica
    Vaccine 26:4795-808. 2008
    ..4% agreement for all types, kappa 0.59). Follow up will continue with yearly or more frequent examinations for at least 4 years for each participant...
  54. doi request reprint Epidemiology of genital Chlamydia trachomatis infection among young women in Costa Rica
    Carolina Porras
    Proyecto Epidemiologico Guanacaste, Fundacion INCIENSA, San Jose, Costa Rica
    Sex Transm Dis 35:461-8. 2008
    ..To investigate Chlamydia trachomatis (Ct) epidemiology among 5829 women 18 to 25 years old, in Costa Rica...
  55. pmc Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis
    Nigel P S Crawford
    Laboratory of Population Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Genet 3:e214. 2007
    ..These data suggest that RRP1B may be a novel susceptibility gene for breast cancer progression and metastasis...
  56. ncbi request reprint DLC-1:a Rho GTPase-activating protein and tumour suppressor
    Marian E Durkin
    Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    J Cell Mol Med 11:1185-207. 2007
    ..Two closely related genes, DLC-2 and DLC-3, may also be tumour suppressors. This review presents the current status of progress in understanding the biological functions of DLC-1 and its relatives and their roles in neoplasia...
  57. ncbi request reprint Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
    Jeffrey N Roberts
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4263, USA
    Nat Med 13:857-61. 2007
    ..In contrast, carrageenan, a polysaccharide present in some vaginal lubricants, prevented infection even in the presence of N-9, suggesting that carrageenan might serve as an effective topical HPV microbicide...
  58. ncbi request reprint Generation of HPV pseudovirions using transfection and their use in neutralization assays
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Methods Mol Med 119:445-62. 2005
    ..Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA)...
  59. pmc Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1
    Yeong Gwan Park
    Laboratory of Population Genetics, National Cancer Institute, Building 41, Room 702, 41 Library Drive, Bethesda, Maryland 20892, USA
    Nat Genet 37:1055-62. 2005
    ..This report is also the first demonstration, to our knowledge, of a constitutional genetic polymorphism affecting tumor metastasis...
  60. pmc E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases
    Xiaolan Qian
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    EMBO J 23:1739-48. 2004
    ..Abrogation of E-cadherin regulation may contribute to the frequent ligand-dependent activation of RTK in tumors...
  61. ncbi request reprint Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1/2) gene products in human kidney epithelial cells through increased E-cadherin/beta-catenin activity
    Shaowei Li
    Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Carcinog 37:98-109. 2003
    ..We conclude that the hamartin/tuberin complex exerted a direct effect on the morphology and adhesive properties of 293 cells through regulation of the level and/or activity of cellular E-cadherin/beta-catenin...